Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Korro Bio ( (KRRO) ) is now available.
On March 9, 2026, Korro Bio entered into a subscription agreement for an oversubscribed private investment in public equity, selling common shares and pre-funded warrants to institutional investors for expected gross proceeds of about $85 million, with closing targeted for March 10, 2026. Led by Venrock Healthcare Capital Partners with participation from several new and existing healthcare-focused funds, the financing underscores investor confidence in Korro’s RNA editing platform and expands its access to non-dilutive public markets alternatives.
Korro said the new capital, combined with $85.2 million in cash and equivalents at year-end 2025, should extend its funding runway into the second half of 2028 and support clinical milestones across multiple programs, including KRRO-121 for hyperammonemia in urea cycle disorders and a GalNAc-conjugated candidate for alpha-1 antitrypsin deficiency. The raise also funds advancement of a longevity and liver health program targeting the AMPKγ1 pathway and is accompanied by a registration rights agreement giving investors resale registration for the new securities, aligning capital structure flexibility with the company’s push toward value-inflecting clinical data.
The most recent analyst rating on (KRRO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
The score is held down primarily by weak financial performance driven by very large ongoing losses and heavy cash burn. Technicals provide some near-term support with the stock above its 20/50-day averages, but overbought momentum signals add risk. Corporate events are mixed (KRRO-121 progress vs trial termination and collaboration pause), while valuation is constrained by a negative P/E and lack of dividend data.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Korro Bio, Inc. is a Cambridge, Mass.-based biopharmaceutical company developing a new class of genetic medicines that edit RNA to treat both rare and highly prevalent diseases. Leveraging its proprietary OPERA RNA editing platform and oligonucleotide-based delivery, the company aims to enable precise, transient single-base edits with established manufacturing and regulatory pathways.
Average Trading Volume: 219,964
Technical Sentiment Signal: Sell
Current Market Cap: $105.3M
See more insights into KRRO stock on TipRanks’ Stock Analysis page.